Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/656051


The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2005)


Description: This report examines the biotechnology sectors in Europe, specifically the markets of France, Germany, the Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- The region's biotech regained its momentum and focus in 2004
This was largely driven by a positive flow of product news, stronger revenue growth, and a continuing consolidation wave
- Driven by advantages of efficiently structured healthcare systems and high accessibility of patient recruitment, the European Union's ten new member states offered impressive capacity for conducting clinical trials
- Demand for rapeseed oil to produce biodiesel surged over the past year, as biofuel production capacity rose dramatically thanks to the EU's measures to move toward a bioeconomy
- In early 2005, the EU was urged by the US to reconsider its rejection of genetically modified (GM) crop technology transfer to developing nations, claiming that the risks of growing biotech crops were being gravely overestimated in Europe
- A strategic rationale, rather than simple survival, drove consolidations
The growing number of transatlantic M&A deals implied that US companies were acknowledging the considerable value among European biotechs
- In 2004, 14 European companies made initial public offerings (IPOs), most of them UK-based biotechs
Experts anticipated a continuation of the flow of IPOs in 2005, albeit in an increasingly selective and value-sensitive market

Industry Profile - Key Points
- Within Europe, Germany, the UK, France, Switzerland, the Netherlands and Sweden remain the region's biotech leaders
- In 2004, the number of public and private biosciences companies across the six major European biotech nations was estimated at more than 2,000, compared with around 1,350 in 2003
- Nanotech is set to play a larger role in the region's biotech industry, as Europe is increasingly strengthening R&D in this rapidly growing, multidisciplinary sector that often intersects with bioscience fields
- More focus is being placed on white biotech (or industrial biotech), as it is expected to spearhead the next revolution in manufacturing industries in Europe (and globally), as nations move toward the creation of bio-economies
- In 2004, most of Europe's technology industries attracted more venture capital than in the previous year
Experts stated that biotech and healthcare companies attracted the largest slice of venture capital in 2004, with -1.3 billion (US$1.8 billion) raised, up 29% from 2003
- In late November, the European Commission (EC) put pressure on five EU member states to lift their national bans on GM products
- Upon the request of the EC, the European Food Safety Authority (EFSA) finalized in late November a document on the risk assessment of GM plants and derived food and feed
Market Trends and Outlook - Key Points
- European biotechs are expected to begin exploring emerging markets (particularly India and China) that offer low cost structures along with other potential benefits
- Therapeutic monoclonal antibodies (mAbs) are set to gradually replace conventional therapies (small molecule drugs) in Europe, driven by comparatively higher efficiency, minimal side effects, and long term cost-effectiveness
- The US- restrictions on embryonic stem cell research (since 2001) and its human cloning ban (since 2003) is causing it to gradually lose ground in this field, while opportunities are opening up across parts of Europe
- Progress in 2004 indicated that the industry is heading toward greater profitability, thanks to a general comeback in investor confidence in the sector, recovering national stock markets, and dynamic progress in product development


Contents: Current Environment
- Sector Overview
- Sector Development
- Mergers, Acquisitions and
Alliances
- Initial Public Offerings
Industry Profile
- Sector Size and Value
- Industry Focus Areas
- Sector Investment
- Policy and Regulatory
Environment
Market Trends and Outlook
- China and India: Dynamic
Prospects for European Biotech
- Monoclonal Antibodies
(mAbs): The Next Therapeutic
Phenomenon
- Europe Stepping Forward in
Stem Cell Research
- Market Outlook
Country Profiles
- France
- Germany
- Netherlands
- Sweden
- Switzerland
- United Kingdom
Currency Conversion Table
The Scope of This Report
Key References
Comparative Data
Sales Contacts




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/656051

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/02/2012 15:41:46
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2005)
Web Address:
http://www.researchandmarkets.com/reports/656051
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €100.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 16/02/2012 15:41:46

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)